Plain-English translation of NCT05156203 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new experimental medication called T-1301, which is taken by mouth as a capsule. T-1301 is designed to fight advanced cancer by blocking multiple proteins that help tumors grow. This is the first time T-1301 is being tested in humans, so the main goal is to learn how safe it is and find the right dose for future studies.
Standard cancer treatments don't work for everyone, and some people cannot tolerate them or choose not to receive them. This medication was developed in the laboratory to offer a new treatment option for people with advanced cancers, and researchers need to test how well it works and how patients tolerate it before it can be widely prescribed.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth as a capsule, either once or twice daily depending on which dose level you're assigned to. The treatment follows a 28-day cycle: you take the medication for 21 days, then have 7 days off. You can continue treatment as long as it's helping and you're tolerating it well, or until the study ends (approximately 12 months after the last participant starts). You'll visit the clinic regularly for blood tests, physical exams, and scans to monitor how the medication is working and check for any side effects.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Taiwan